Drug Topics January 30, 2025
A survey conducted by 3 Axis Advisors revealed potential impacts of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.
In the form of payment delays, cash flow shortfalls, and overall revenue losses, the 10 drugs whose price negotiations are set to take effect January 1, 2026, present a detrimental financial risk to community pharmacies in the US. Highlighted by a recent analysis of the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program (MDPNP), experts believe it could lead to pharmacy closures, reduced prescription access, and further financial pitfalls for independent pharmacies.
“Everyone wants to reduce drug costs for seniors and taxpayers,” said National Community Pharmacists Association (NCPA) CEO B. Douglas Hoey, MBA, in a news release.1 “But, as...
Today's Sponsors
Today's Sponsor